A multicenter, open-label, extension study of the long-term safety of pramlintide in subjects with type 1 diabetes mellitus completing protocol 137-150

Trial Profile

A multicenter, open-label, extension study of the long-term safety of pramlintide in subjects with type 1 diabetes mellitus completing protocol 137-150

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2015

At a glance

  • Drugs Pramlintide (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Sponsors Amylin Pharmaceuticals; AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Aug 2006 Status change
    • 01 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top